Please login to the form below

Not currently logged in
Email:
Password:

dabigatran

This page shows the latest dabigatran news and features for those working in and with pharma, biotech and healthcare.

Bad news for Portola as CHMP considers Factor Xa drugs

Bad news for Portola as CHMP considers Factor Xa drugs

In the meantime, Boehringer Ingelheim’s rival NOAC Pradaxa (dabigatran) - which works by inhibiting thrombin - remains the only new anticoagulant on the market with a reversal agent available.

Latest news

More from news
Approximately 11 fully matching, plus 89 partially matching documents found.

Latest Intelligence

  • Interview: Allan Hillgrove, Boehringer Interview: Allan Hillgrove, Boehringer

    American College of Cardiology (ACC) to educate cardiologists in China about stroke prevention in atrial fibrillation (AF) – a condition for which Boehringer markets Pradaxa (dabigatran). “

  • Modern anticoagulants threaten status quo Modern anticoagulants threaten status quo

    Between March 2011 and February 2012, dabigatran etexilate sales crossed the 'blockbuster' $1bn threshold. ... Interestingly, a study published in Stroke in March 2012 found that dabigatran etexilate was a cost-effective alternative to warfarin.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics